Vivos Inc. Reports Widened Q1 Loss, Material Weakness in Controls, and Significant Dilutive Financing Amidst Going Concern Warning

summarizeSummary

Vivos Inc. reported a widened Q1 net loss and a material weakness in internal controls, while raising significant dilutive capital to address its ongoing going concern issues and fund strategic initiatives.

check_boxKey Events

• Widened Net Loss and Going Concern Warning

  The company reported a net loss of $1.18 million for Q1 2026, a significant increase from $0.83 million in Q1 2025, and reiterated substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient cash.

• Material Weakness in Internal Controls

  Management identified a material weakness in disclosure controls and procedures, specifically related to proper segregation of duties, rendering them ineffective as of March 31, 2026.

• Significant Dilutive Capital Raise

  Vivos Inc. raised $2.20 million in March 2026 and an additional $0.65 million in April 2026 through the sale of 35.2 million common shares and 38.6 million warrants via Regulation A+ Offerings and concurrent private placements, representing substantial dilution to existing shareholders.

• Strategic Progress in Product Development and Manufacturing

  The company is actively working on resubmitting its FDA Investigational Device Exemption (IDE) for RadioGel human therapy, engaging a regulatory expert, and diversifying manufacturing with new domestic and international facilities targeted for 2026 operation. The IsoPet animal therapy division reported a 1,200% year-over-year increase in administered therapies and aims for breakeven in 2026.

auto_awesomeAnalysis

Vivos Inc. continues to operate under a going concern warning, with its net loss widening significantly in Q1 2026. The company disclosed a material weakness in its internal controls related to segregation of duties, which is a serious governance concern. To fund operations and development, Vivos Inc. undertook substantial dilutive financing, raising $2.85 million through common stock and warrant sales in March and April 2026. Despite these financial challenges, the company is actively pursuing FDA approval for its RadioGel human therapy, diversifying manufacturing, and reporting strong growth in its IsoPet animal therapy division, targeting breakeven in 2026.